Cerebrolysin for vascular dementia.
Cui S, Chen N, Yang M, Guo J, Zhou M, Zhu C, He L · 2019 · The Cochrane database of systematic reviews
What does this source report?
Cochrane found possible cognitive and global-function signals but a weak, very low-certainty evidence base.
- Population and setting
- Six vascular-dementia trials; 597 participants
- Evidence type
- Review
- Preparation
- Porcine brain-derived peptide mixture; equivalence to other hydrolysates is not assumed
- Source language
- Indexed English abstract; original language varies
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- High risk of bias, heterogeneity and potentially clinically small effects. No quality-of-life or caregiver-burden data; industry support where funding was reported.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Source access and review scope
Citation and indexed abstract checked. Full methods, funding and risk of bias have not been comprehensively appraised.
Recorded source-check date: 2026-09-30. This date does not imply a completed systematic review.
Source provenance: Journal publication
Cite and trace this record
Original source: Cui S, Chen N, Yang M, Guo J, Zhou M, Zhu C, He L. Cerebrolysin for vascular dementia. The Cochrane database of systematic reviews 2019.
Molekul research summary: https://molekul.io/research/cbl-31710397. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry